Cargando…

Potential Targeted Therapies in Ovarian Cancer

Background: We aimed to identify somatic pathogenic and likely pathogenic mutations using next-generation sequencing (NGS). The mutational findings were held against clinically well-described data to identify potential targeted therapies in Danish patients diagnosed with high-grade serous ovarian ca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sisman, Yagmur, Vestergaard, Lau Kræsing, de Oliveira, Douglas Nogueira Perez, Poulsen, Tim Svenstrup, Schnack, Tine Henrichsen, Høgdall, Claus, Høgdall, Estrid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9697427/ https://www.ncbi.nlm.nih.gov/pubmed/36355495 http://dx.doi.org/10.3390/ph15111324

Ejemplares similares

Organoids and epithelial ovarian cancer - a future tool for personalized treatment decisions? (Review)
por: Sisman, Yagmur, et al.
Publicado: (2022)

The potential role of infectious agents and pelvic inflammatory disease in ovarian carcinogenesis
por: Ingerslev, Kasper, et al.
Publicado: (2017)

The prevalence of EBV and CMV DNA in epithelial ovarian cancer
por: Ingerslev, Kasper, et al.
Publicado: (2019)

Genomic Sub-Classification of Ovarian Clear Cell Carcinoma Revealed by Distinct Mutational Signatures
por: Oliveira, Douglas V. N. P., et al.
Publicado: (2021)

High-risk HPV is not associated with epithelial ovarian cancer in a Caucasian population
por: Ingerslev, Kasper, et al.
Publicado: (2016)

Oncomine™ Comprehensive Assay v3 vs. Oncomine™ Comprehensive Assay Plus
por: Vestergaard, Lau K., et al.
Publicado: (2021)

Next Generation Sequencing Technology in the Clinic and Its Challenges
por: Vestergaard, Lau K., et al.
Publicado: (2021)

miR-21 Expression in Cancer Cells may Not Predict Resistance to Adjuvant Trastuzumab in Primary Breast Cancer
por: Nielsen, Boye Schnack, et al.
Publicado: (2014)

Strategies for data normalization and missing data imputation and consequences for potential diagnostic microRNA biomarkers in epithelial ovarian cancer
por: Lopacinska-Jørgensen, Joanna, et al.
Publicado: (2023)

Diagnostic plasma miRNA-profiles for ovarian cancer in patients with pelvic mass
por: Oliveira, Douglas Nogueira Perez, et al.
Publicado: (2019)

Identification and validation of potential prognostic and predictive miRNAs of epithelial ovarian cancer
por: Prahm, Kira Philipsen, et al.
Publicado: (2018)

Mucosal expression of PI3, ANXA1, and VDR discriminates Crohn’s disease from ulcerative colitis
por: James, Jaslin Pallikkunnath, et al.
Publicado: (2023)

Residual tumor and primary debulking surgery vs interval debulking surgery in stage IV epithelial ovarian cancer
por: Sørensen, Sarah Mejer, et al.
Publicado: (2022)

Integrated microRNA and mRNA signatures associated with overall survival in epithelial ovarian cancer
por: Lopacinska-Jørgensen, Joanna, et al.
Publicado: (2021)

Gene expression profile association with poor prognosis in epithelial ovarian cancer patients
por: Oliveira, Douglas V. N. P., et al.
Publicado: (2021)

DNA Methylation in Ovarian Tumors—a Comparison Between Fresh Tissue and FFPE Samples
por: Oliveira, Douglas V.N.P., et al.
Publicado: (2021)

Searching for new biomarkers in ovarian cancer patients: Rationale and design of a retrospective study under the Mermaid III project
por: Hentze, Julie L., et al.
Publicado: (2017)

Noncoding RNA (ncRNA) Profile Association with Patient Outcome in Epithelial Ovarian Cancer Cases
por: Oliveira, Douglas V. N. P., et al.
Publicado: (2020)

Identification of stably expressed microRNAs in plasma from high-grade serous ovarian carcinoma and benign tumor patients
por: Petersen, Patrick H.D., et al.
Publicado: (2023)

MicroRNA characteristics in epithelial ovarian cancer
por: Prahm, Kira Philipsen, et al.
Publicado: (2021)

Test of the FlashFREEZE unit in tissue samples freezing for biobanking purposes
por: Biskup, Edyta, et al.
Publicado: (2022)

Outstanding Response to Sorafenib in a Patient with Metastatic Gastrointestinal Stromal Tumour
por: Brinch, Charlotte, et al.
Publicado: (2021)

PAPP-A proteolytic activity enhances IGF bioactivity in ascites from women with ovarian carcinoma
por: Thomsen, Jacob, et al.
Publicado: (2015)

Improved migration of tumor ascites lymphocytes to ovarian cancer microenvironment by CXCR2 transduction
por: Idorn, Manja, et al.
Publicado: (2017)

Expression Stability Analysis of Candidate References for Normalization of RT-qPCR Data Using RefSeeker R package
por: Petersen, Patrick H.D., et al.
Publicado: (2023)

DNA sequencing of cytopathologically inconclusive EUS-FNA from solid pancreatic lesions suspicious for malignancy confirms EUS diagnosis
por: Plougmann, Julie Isabelle, et al.
Publicado: (2019)

Survival and recurrence in stage II endometrial cancers in relation to uterine risk stratification after introduction of lymph node resection and omission of postoperative radiotherapy: a Danish Gynecological Cancer Group Study
por: Ørtoft, Gitte, et al.
Publicado: (2019)

YKL-40 tissue expression and plasma levels in patients with ovarian cancer
por: Høgdall, Estrid VS, et al.
Publicado: (2009)

Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization for Low and High Throughput HER2 Genetic Testing
por: Poulsen, Tim S., et al.
Publicado: (2013)

Circulating Antinuclear Antibodies in Patients with Pelvic Masses Are Associated with Malignancy and Decreased Survival
por: Heegaard, Niels H. H., et al.
Publicado: (2012)

Lymph-vascular space invasion (LVSI) as a strong and independent predictor for non-locoregional recurrences in endometrial cancer: a Danish Gynecological Cancer Group Study
por: Ørtoft, Gitte, et al.
Publicado: (2019)

Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer
por: Palshof, Jesper Andreas, et al.
Publicado: (2017)

Markers aiding the diagnosis of chondroid tumors: an immunohistochemical study including osteonectin, bcl-2, cox-2, actin, calponin, D2-40 (podoplanin), mdm-2, CD117 (c-kit), and YKL-40
por: DAUGAARD, SØREN, et al.
Publicado: (2009)

Tagging Single Nucleotide Polymorphisms in the BRIP1 Gene and Susceptibility to Breast and Ovarian Cancer
por: Song, Honglin, et al.
Publicado: (2007)

Clinical validation of chemotherapy predictors developed on global microRNA expression in the NCI60 cell line panel tested in ovarian cancer
por: Prahm, Kira Philipsen, et al.
Publicado: (2017)

Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma?
por: Gronlund, B, et al.
Publicado: (2004)

ABCG2 Protein Levels and Association to Response to First-Line Irinotecan-Based Therapy for Patients with Metastatic Colorectal Cancer
por: Palshof, Jesper Andreas, et al.
Publicado: (2020)

Risk factors for early death among ovarian cancer patients: a nationwide cohort study
por: Mosgaard, Berit Jul, et al.
Publicado: (2019)

Real‐life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (RESPONSE trial)
por: Marth, Christian, et al.
Publicado: (2022)

Association between Common Germline Genetic Variation in 94 Candidate Genes or Regions and Risks of Invasive Epithelial Ovarian Cancer
por: Quaye, Lydia, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_5i3kd168beilv62mdumi0vgn8j